Relevant bibliographies by topics / Adjuvant treatment

Academic literature on the topic 'Adjuvant treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant treatment"

1

Hauschild and Volkenandt. "Adjuvant treatment of malignant melanoma." Therapeutische Umschau 56, no. 6 (June 1, 1999): 324–29. http://dx.doi.org/10.1024/0040-5930.56.6.324.

Full text
Abstract:
Das Ziel einer adjuvanten Therapie nach operativer Entfernung eines Melanoms besteht in der Unterdrückung der Ausbreitung eventuell vorhandener, klinisch inapparenter Mikrometastasen. Vergleiche verschiedener Therapieverfahren (z.B. adjuvant applizierte Chemotherapeutika) mit unbehandelten Kontrollkollektiven ließen in der Vergangenheit gelegentlich eine Wirksamkeit erhoffen. Große, multizentrische, kontrollierte und prospektiv randomisierte Studien konnten jedoch keinen eindeutigen Vorteil einer adjuvanten Chemotherapie in bezug auf die Verlängerung der rezidivfreien Überlebenszeit oder der Gesamtüberlebenszeit erkennen. Eine adjuvante Zytostatika-Therapie kann daher außerhalb von klinischen Studien derzeit nicht mehr empfohlen werden. Derzeitige Hoffnungsträger sind insbesondere die rekombinant herstellbaren Zytokine, vor allem die Interferone. Drei große und randomisierte Studien zur adjuvanten Therapie mit Interferon-alpha von Hochrisiko-Patienten zeigten übereinstimmend eine verbesserte rezidivfreie Überlebenszeit; der Einfluß der Interferon-alpha-Behandlung auf die Heilungsraten bleibt jedoch weiterhin unklar. Ebenso kann derzeit zur optimalen Dosis und Dauer der Interferon-alpha-Therapie noch nicht eindeutig Stellung bezogen werden. Melanom-Patienten mit einem hohen Metastasierungsrisiko sollten in nationale und internationale prospektiv-randomisierte Therapieprotokollen eingeschlossen werden, deren Ergebnisse zu allgemeinverbindlichen Empfehlungen zur adjuvanten Melanomtherapie führen können.
APA, Harvard, Vancouver, ISO, and other styles
2

Le Chevalier, Thierry. "Adjuvant treatment." American Journal of Cancer 3, Supplement 2 (2004): 3–5. http://dx.doi.org/10.2165/00024669-200403992-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sultana, Asma, John Neoptolemos, and Paula Ghaneh. "Adjuvant treatment." HPB 8, no. 5 (October 2006): 352–64. http://dx.doi.org/10.1080/13651820600804146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Snipes, C. E., and G. D. Wills. "Influence of Temperature and Adjuvants on Thidiazuron Activity in Cotton Leaves." Weed Science 42, no. 1 (March 1994): 13–17. http://dx.doi.org/10.1017/s0043174500084095.

Full text
Abstract:
A laboratory study was conducted to determine the effects of two adjuvants and temperatures at time of treatment on efficacy, absorption, and translocation of thidiazuron defoliant on cotton. Five days after treatment at 30/21 C day/night temperatures, leaf drop was 17% with no adjuvant, 37% with addition of crop oil concentrate, 40% with ammonium sulfate, and 75% with two adjuvants combined. At 21/13 C day/night temperatures, there was less than 10% leaf drop with all treatments. At 10 d after treatment, leaf drop was not different among treatments at the high or low temperatures. Shoot regrowth at high and low temperature was reduced 55 to 60% with addition of both adjuvants and 44 to 50% with each adjuvant or with no adjuvant when compared to plants defoliated by hand. Absorption of14C-thidiazuron was not affected by variations in temperature during the time of treatment but was affected by adjuvants. With no adjuvants, absorption was 7 to 10%. With 1.25% by vol crop oil concentrate, absorption was 33 to 46%. Addition of ammonium sulfate resulted in 18 to 19% absorption, and the combination of ammonium sulfate and crop oil concentrate increased absorption to 65 to 68%. There was no movement of radiolabel away from treated leaves as determined by autoradiographs of treated plants.
APA, Harvard, Vancouver, ISO, and other styles
5

Garcia, Luiz C., Guilherme H. Carraro, Sandro Felema, Allison J. Fornari, Leandro J. V. Sformi, and Thiago M. Inagaki. "Adjuvants used in fungicide spraying on soybean plants." Spanish Journal of Agricultural Research 22, no. 3 (June 13, 2024): e1003. http://dx.doi.org/10.5424/sjar/2024223-20497.

Full text
Abstract:
Aim of study: An adjuvant is a material that is added to a spray carrier to improve the application technology's efficiency but lacks phytosanitary qualities. Our objective was to determine the best option of combining fungicides and adjuvants to control soybean (Glycine max) leaf diseases in three cropping seasons. Area of study: The experiment was developed in the Campos Gerais region (PR - Brazil). Material and methods: The five treatments consisted of 1) control (without applying fungicides on soybean plants); 2) fungicide application on soybean plants without adjuvant; 3) fungicide with adjuvant based on mineral oil; 4) fungicide with adjuvant based on lecithin and 5) propionic acid and fungicide with 50% of the dose of adjuvant based on mineral oil + 50% of the dose of surfactant adjuvant based on lecithin and propionic acid. The analyzed variables were the physicochemical characteristics of the spray carrier, the incidence and severity of diseases, and the yield components. A completely randomized design was used to study the physicochemical characteristics of the carrier and in randomized blocks for the field experiment. We used five replicates per treatment. Main results: No foaming and mixing incompatibility of the spray carrier was observed in any treatment. The adjuvant based on lecithin and propionic acid further acidified the spray carrier and presented the same surface tension as mineral oil. The soybean plants that did not receive chemical treatment had a higher occurrence of diseases, which reduced the productive potential. Research highlights: Adding adjuvants to the spray carrier did not increase the performance of fungicides in controlling diseases and did not affect the yield components.
APA, Harvard, Vancouver, ISO, and other styles
6

Pujisiswanto, Hidayat, Yayuk Nurmiaty, Nanik Sriyani, and Annisa Efrima. "Pengaruh Ekstrak Buah Lerak (Sapindus rarak) dan Beberapa Adjuvan terhadap Perkecambahan Gulma Fimbristylis miliacea." JURNAL AGROTROPIKA 20, no. 2 (October 3, 2021): 104. http://dx.doi.org/10.23960/ja.v20i2.5205.

Full text
Abstract:
Adjuvant is an ingredient added in a formulation to increase the effectiveness of lerak fruit in inhibiting weeds. This study aims to determine the type of adjuvant in lerak fruit extract that can increase the inhibition of germination of Fimbristylis miliacea and to determine the type of adjuvant in lerak fruit extract that is most effective in inhibiting the germination of F. miliacea. The research was conducted from December 2019 to March 2020 in the Weed Laboratory, Faculty of Agriculture, University of Lampung. This study used a Completely Randomized Design (CRD) to determine the type of adjuvant given to lerak fruit extract on F. miliacea germination with 4 replications. The treatments consisted of lerak fruit extract, lerak fruit extract + VCO adjuvant, lerak fruit extract + KAO adjuvant, lerak fruit extract + Polysorbate 80 adjuvant, and control. The Bartlett test was used to test the homogeneity of variance, if the assumptions of the analysis of variance were met, then the mean value of the treatment was continued with the Least Significant Difference (LSD) test at the 5% level. The results showed that adjuvants and without adjuvants added to lerak fruit extract at a concentration of 50% (500 g/l) were able to suppress the percentage of germination and the speed of germination of Fimbristylis miliace seeds.Keywords: adjuvants, lerak fruit extract, Fimbristylis miliacea, weed
APA, Harvard, Vancouver, ISO, and other styles
7

Boccon-Gibod, Laurent. "Adjuvant treatment to surgery." BJU International 100, s2 Prostate Can (July 2007): 40–43. http://dx.doi.org/10.1111/j.1464-410x.2007.06953.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moreno Nogueira, J. A., M. Valero Arbizu, and R. Pérez Temprano. "Adjuvant Treatment of Melanoma." ISRN Dermatology 2013 (February 17, 2013): 1–17. http://dx.doi.org/10.1155/2013/545631.

Full text
Abstract:
Melanomas represent 4% of all malignant tumors of the skin, yet account for 80% of deaths from skin cancer.While in the early stages patients can be successfully treated with surgical resection, metastatic melanoma prognosis is dismal. Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene. The treatment of choice for localised primary cutaneous melanoma is surgery plus lymphadenectomy if regional lymph nodes are involved. The justification for treatment in addition to surgery is based on the poor prognosis for high risk melanomas with a relapse index of 50–80%. Patients included in the high risk group should be assessed for adjuvant treatment with high doses of Interferon-α2b, as it is the only treatment shown to significantly improve disease free and possibly global survival. In the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.
APA, Harvard, Vancouver, ISO, and other styles
9

Rubens, R. D. "Breast cancer: Adjuvant treatment." European Journal of Cancer 28, no. 2-3 (February 1992): 620–22. http://dx.doi.org/10.1016/s0959-8049(05)80111-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sehati, Nouzhan, and Linda M. Liau. "Adjuvant Treatment for Gliomas." Contemporary Neurosurgery 25, no. 15 (July 2003): 1–9. http://dx.doi.org/10.1097/00029679-200307310-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adjuvant treatment"

1

Kho, Sunn Sunn Patricia. "Optimising Adjuvant Treatment for Colorectal Cancer." Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/9470.

Full text
Abstract:
The aim of the thesis is to optimize adjuvant treatment for colorectal cancer (CRC) patients. CRC treatment has improved over the decades resulting in improved overall survival of patients. The 5-year overall survival for CRC in the US between 1975 – 1979 was 50.6% while by 2004; it had improved to 65.9%. This is largely due to improvements in surgical and radiation techniques, screening initiatives and more effective chemotherapy drugs. However, when compared to the 5-year overall survival for breast cancer in 2004 of 89.9% (SEER data), it is clear that further improvements in CRC treatment are needed. This thesis evaluated different approaches to further improve overall survival rates and to reduce the acute and late toxicities associated with adjuvant treatment. One of the approaches was to attempt to personalize treatment for colorectal cancer patients using prognostic and predictive biomarkers. The group of patients selected for review were Stage C colon and rectal patients as the risk of recurrence is very high and the 5 year overall survival remains poor at 28% for colon cancer and 33% for rectal cancer. In this era of personalized medicine, the hope is to be able to tailor treatment regimens according to the patient and disease stage to reduce toxicity and improve efficacy. A retrospective analysis of the survival of Stage C rectal cancer patients in a public teaching hospital who received adjuvant chemotherapy after a curative resection was conducted to evaluate the role of adjuvant chemotherapy alone without radiotherapy. An original research study evaluating the role of a candidate marker, s100A4 in the treatment of Stage C colon cancer was also performed to evaluate the possible role of a new candidate biomarker s100A4 in the prognostication of Stage C colon cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Smeenk, Henri Gerard. "Surgical and adjuvant treatment of pancreatic cancer." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/13713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bossaer, John B., and Christian M. Thomas. "Adjuvant Treatment of Newly Diagnosed Breast Cancer." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/2313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Buijs, Ciska. "Long-term side effects of adjuvant breast cancer treatment." [S.l. : Groningen : s.n. ; University Library of Groningen] [Host], 2008. http://irs.ub.rug.nl/ppn/306087480.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mastrandrea, Nicholas Joseph. "Pentoxifylline As An Adjuvant Treatment In Renal Cell Carcinoma." Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/337293.

Full text
Abstract:
Cyclin D1, a proto-oncogene, is required for progression from the G1 phase into the S phase of the cell cycle. Over-expression of cyclin D1 causes an increase in cell cycle progression and cell proliferation, implicating it in a variety of cancers including renal cell carcinoma (RCC). The rodent RCC cell model, QTRRE, and human RCC cell models, ACHN, 786-O and Caki-2, exhibit elevated levels of cyclin D1. Pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor, is an FDA-approved hemorheologic agent used to treat intermittent claudication, stemming from peripheral vascular diseases, as well as other diseases involving defective locoregional blood flow. Treatment of QTRRE, ACHN, 786-O and Caki-2 with PTX caused a time- (0-24 hrs) and dose- (0-1.0 mg/mL) dependent decrease of cyclin D1 protein and p-Rb levels in whole cell lysate as well as cytosolic and nuclear fractions, albeit, to different extents within the models. Concomitant with cyclin D1 and p-Rb decrease, enhanced G1 phase cell cycle arrest was observed in the RCC models. Mechanistic studies in these RCC cell models were carried out to determine PTXs mechanism of action with regard to cyclin D1 protein level decrease. RT-PCR analysis showed no significant changes in cyclin D1 mRNA copy number in time- (0-24 hrs) and dose- (0-1.0 mg/mL) dependent PTX treatments. However, such treatments caused decrease in p-4EBP1 (Ser65), p-4EBP1 (Thr70), and p-4EBP1 (Thr37/46). Because PTX's ability to decrease cyclin D1 protein was prevented in the presence of the proteasome inhibitor, MG-132, studies were performed to determine whether cyclin D1 stability was decreased during PTX treatment. Cyclin D1 degradation is initiated by phosphorylation of residue Thr286 by GSK-3β. Inhibition of GSK-3β with LiCl or knockdown via siRNA in the presence of PTX failed to block cyclin D1 decrease. Moreover, PTX treatment in the presence of MG-132 revealed no significant increase in cyclin D1 p-Thr286 compared to control. Finally, using the protein synthesis inhibitor, CHX, PTX caused no significant decrease in cyclin D1 t₁/₂ (wt-HA and T286A-HA) compared to control. Sorafenib, a broad-spectrum (cRAF, bRAF, KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-β) kinase inhibitor, is FDA-approved for the treatment of RCC. Studies with sorafenib and PTX in the ACHN cell model were carried out to determine PTXs possible adjuvant role in inhibiting cell growth via cyclin D1 decrease and G1 phase arrest. MTS data showed PTX potentiates the anti-proliferative effects of sorafenib. PTX pre-treatment for 24 hrs was also lowered the effective dose of sorafenib from 50 μM to 5 μM. Further, ACHN xenograft tumor volumes from mice treated with PTX and sorafenib displayed significantly higher tumor growth inhibition compared to either drug treatment alone or vehicle. Finally, drug treated ACHN xenograft tissue displayed significantly lower cyclin D1, p-RB and p-4EBP1 levels. These results demonstrate a novel anti-cancer property of PTX and suggest its use as a possible adjuvant therapy in RCC treatment should be further explored.
APA, Harvard, Vancouver, ISO, and other styles
8

Giallourou, Natasa. "Watercress as a nutritional adjuvant treatment in breast cancer." Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/76171/.

Full text
Abstract:
Breast cancer is a leading cause of cancer related mortality globally, and epidemiological studies suggest a link between healthy nutrition and cancer prevention. Members of the Brassicaceae family, including watercress, have been extensively studied for their anti-cancer and anti-genotoxic potential. Watercress has a complex phytonutrient profile characterised by high levels of carotenoids, flavonols and glucosinolates. Extracts of watercress exhibit strong antioxidant capacity in vitro. Watercress and its components have been associated with the inhibition of the three stages of carcinogenesis: initiation, proliferation and metastasis in in vitro cancer cell models. Phenethyl isothiocyanate (PEITC) is a glucosinolate break-down product and watercress is the richest dietary source of it. It has received considerable attention for its anti-cancer properties and has been tested in a number of clinical trials. In this thesis, the effects of crude watercress extract and PEITC on the metabolic and phenotypic responses in breast cancer and healthy breast tissue cell lines were examined. Radiotherapy is the most common treatment modality for breast cancer patients; it functions by killing cancer cells but it simultaneously damages healthy tissues. We set out to examine synergistic responses to irradiation and watercress or PEITC exposures in breast cancer cells and we further investigated whether watercress or PEITC can be protective against radiation induced collateral damage. Watercress and PEITC effectively modulated important cancer cell metabolic pathways associated with anti-cancer endpoints such as cell cycle arrest and DNA damage. In this thesis, PEITC has been shown to enhance the sensitivity of cancer cells to irradiation making the cancer killing process more effective, whereas watercress can protect healthy breast cells from radiation induced damage. These observations appear to be mediated by the ability of PEITC and other phytochemicals in watercress to interact with the antioxidant glutathione. The results obtained from this work remain to be validated in a clinical setting.
APA, Harvard, Vancouver, ISO, and other styles
9

Wirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.

Full text
Abstract:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
10

Andersson, Anna. "Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours." Thesis, Linköping University, Engelska: Faculty of Health Sciences, Medical Programme, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11060.

Full text
Abstract:

Background: GISTs are gastrointestinal mesenchymal tumours that express the type III receptor tyrosine kinase KIT. The KIT proto-oncogene encodes the receptor KIT. Most GISTs have gain-of-function mutations in the KIT or PDGFRA gene. The tyrosine kinase is therefore continuously activated leading to ligand-independent dimerization. Imatinib mesylate (Glivec®) is considered to be the first-line palliative treatment. The activated form of the KIT receptor tyrosine kinase is inhibited by imatinib. The aim of the study was to compare the survival of patients treated with either adjuvant or down-staging imatinib with historic controls treated with radical surgery (R0) only.

Methods: A historic control group was chosen from a population-based series from western Sweden (population 1.6 million) that matched the adjuvant (n=23) and down-staging (n=7) groups respectively. Mutation analysis was performed in all cases with bidirectional direct sequencing. The recurrence-free survival was calculated.

Results: There was only one recurrence (4 %) in the adjuvant group, and no recurrences in the down-staging study group, compared to 32/48 patients (67 %) in the control group. Tumour size decreased in diameter from 20 cm to 11 cm with down-staging treatment.

Conclusion: Adjuvant imatinib improves recurrence-free survival in R0 resected patients. Down-staging treatment with imatinib is recommended for patients with large tumours or metastases. The importance of mutation analysis was established.

APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Adjuvant treatment"

1

S, Abi-Aad Antoine, ed. Adjuvant treatment in urological cancer. New York: Parthenon Pub. Group, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

International Congress on Neo-Adjuvant Chemotherapy (2nd 1988 Paris, France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the first International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 19-21 February 1988. Paris: INSERM, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

International, Congress on Neo-Adjuvant Chemotherapy (1st 1985 Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the first International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 6-9 November, 1985. London: Libbey, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

International, Congress on Neo-Adjuvant Chemotherapy (2nd Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the Second International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 19-21 February 1988. London: Libbey, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

International Conference on the Adjuvant Therapy of Cancer. (5th 1987 Tucson, Ariz.). Adjuvant therapy of cancer V. Orlando: Grune & Stratton, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

International, Conference on the Adjuvant Therapy of Cancer (6th 1990 Tucson Ariz ). Adjuvant therapy of cancer VI: Proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 7-10, 1990. Philadelphia: Saunders, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Patrick, Quillin, Williams R. Michael, Cancer Treatment Research Foundation, and American College of Nutrition (U.S.), eds. Adjuvant nutrition in cancer treatment: 1992 symposium proceedings. Arlington Heights, IL: Cancer Treatment Research Foundation, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International, Conference on the Adjuvant Therapy of Cancer (8th 1996 Scottsdale Ariz ). Adjuvant therapy of cancer VIII: Proceedings of the Eighth International Conference on the Adjuvant Therapy of Cancer, Scottsdale, Arizona, March, 1996. Philadelphia: Lippincott-Raven, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

International Congress on Neo-Adjuvant Chemotherapy. (3rd 1991 Palais des Congrès, Paris, France). Ondansetron and chemotherapy induced emesis: 3rd International Congress on Neo-Adjuvant Chemotherapy. Paris: Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Servan-Schreiber, David. Antyrak: Nowy styl życia. 6th ed. Warszawa: Wydawnictwo Albatros Andrzej Kuryłowicz, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Adjuvant treatment"

1

Barmpounis, Vasileios, and George Kesisis. "Planning Adjuvant Treatment." In Breast Cancer Essentials, 569–77. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73147-2_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ishikawa, Toshiaki, and Hiroyuki Uetake. "Adjuvant Chemotherapy." In Recent Advances in the Treatment of Colorectal Cancer, 81–100. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-3050-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cho, Haruhiko. "Adjuvant and Neoadjuvant Treatment." In Gastrointestinal Stromal Tumor, 129–44. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3206-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jaffe, Norman. "Adjuvant Chemotherapy in Osteosarcoma." In Cancer Treatment and Research, 219–37. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-1-4419-0284-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vergote, I. B., C. G. Tropé, L. N. De Vos, J. Kærn, V. M. Abeler, M. Winderen, and E. O. Pettersen. "Adjuvant treatment of ovarian carcinoma." In Cancer Treatment An Update, 464–68. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_96.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Romond, Edward H., Lawrence A. Mendelsohn, and John S. MacDonald. "Adjuvant therapy of gastrointestinal cancer." In Cancer Treatment and Research, 273–95. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2031-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Costa, Frederico, Gary Schwartz, and David Kelsen. "Adjuvant chemotherapy in gastric adenocarcinomas." In Cancer Treatment and Research, 41–63. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-4977-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wiegel, T. "Adjuvant Radiotherapy following Radical Prostatectomy." In Three-Dimensional Radiation Treatment, 145–51. Basel: KARGER, 2000. http://dx.doi.org/10.1159/000061255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guglielmi, Alfredo, Andrea Ruzzenente, and Calogero Iacono. "Adjuvant and Palliative Treatments." In Surgical Treatment of Hilar and Intrahepatic Cholangiocarcinoma, 233–37. Milano: Springer Milan, 2007. http://dx.doi.org/10.1007/978-88-470-0729-1_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pollard, Annabel. "Supportive Care During Adjuvant Treatment." In Adjuvant Therapy for Breast Cancer, 219–38. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-75115-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant treatment"

1

Dall, P., T. Koch, G. Lenzen, T. Kuhn, C. Hielscher, D. Reichert, M. Maasberg, P. Ehscheidt, H. Eustermann, and G. Fischer. "P1-12-21: Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p1-12-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Biegel, U., U. von Bodungen, K. Ruess, M. Reif, Y. Knauf, and N. Stratmann. "Mistletoe in adjuvant cancer treatment of companion animals." In 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) in cooperation with the French Society of Pharmacognosy AFERP. © Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-3399644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rogosic, Srdan, Charlotte Patterson, Jack Bartram, Vesna Pavasovic-Jovanovic, Sujith Samarasinghe, Philip Ancliff, Anupama Rao, David O’Connor, Ajay Vora, and Sara Ghorashian. "89 Chronic disseminated candidiasis treated with adjuvant corticosteroid treatment." In GOSH Conference 2020 – Our People, Our Patients, Our Hospital. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2020. http://dx.doi.org/10.1136/archdischild-2020-gosh.89.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bianchini, G., L. Pusztai, T. Iwamoto, CM Kelly, M. Zambetti, A. Fasolo, G. Del Conte, L. Santarpia, WF Symmans, and L. Gianni. "S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-s1-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Alukal, Anila Tresa, Rema Anil Prabhakaran, Suchetha Jyothish, Siva J. Ranjith, and Dhanya Dinesh. "#712 Adjuvant treatment after radical hysterectomy for early cervical cancer." In ESGO 2023 Congress. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/ijgc-2023-esgo.178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cunha, Matheus Almeida Ribeiro da, João Gustavo dos Anjos Morais Oliveira, Gabriela Sarno Brandão, Ana Flávia Paiva Bandeira Assis, Leonardo Mattos Santos, Isaac Rêgo Purificação, Isabella Trindade Lopes Alves, Mariana Portella Lopes Cruz, and Raimundo Nonato Ribeiro Fernandes. "Clinical effects of nonpharmacological treatment of ADHD." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.488.

Full text
Abstract:
Background: Though pharmacotherapy of Attention Deficit Hyperactivity Disorder (ADHD) is widespread, some patients suffer with side effects or do not improve with it. Objectives: Evaluate clinical outcomes of non-pharmacological therapy on ADHD. Design and Setting: This is a literature review, produced in Bahiana School of Medicine and Public Health. Methods: Articles published between 2011 and 2021 were taken from PubMed, using the following search: (“Non-pharmacological treatment” OR “Non- pharmacological therapy” OR “Non-pharmacological intervention” OR “Non-drug treatment” OR “Non-drug therapy” OR “Adjuvant treatment” OR “Adjuvant therapy”) AND (“ADHD” OR “Attention Deficit-Hyperactivity Disorder”). Studies that did not match this review’s objectives were excluded. Results: 20 of the 57 articles found, were selected. Reviews that approach treatment in general indicate non-pharmacological therapy specially when there are obstacles to use of drugs, but highlight the lack of studies with methodological quality in this field. Clinical studies indicate reduction of symptoms through neurofeedback, transcranial magnetic stimulation, and aerobic exercises. One of the interventions with the most articles was nutritional supplementation, though most of them did not find significant improvement. Conclusions: Non-pharmacological treatment of ADHD is a relevant alternative, especially when there is no response to medication, but studies with better methodological quality are necessary.
APA, Harvard, Vancouver, ISO, and other styles
7

Korbelik, Mladen, Ivana Cecic, Jinghai Sun, and David J. Chaplin. "Examples of adjuvant treatment enhancing the antitumor effect of photodynamic therapy." In BiOS '99 International Biomedical Optics Symposium, edited by Thomas J. Dougherty. SPIE, 1999. http://dx.doi.org/10.1117/12.351507.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Campiglio, M., E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, and S. Menard. "Observational GHEA Study: Adjuvant-Trastuzumab-Treatment of HER2-Positive Breast Carcinoma." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

GÓMEZ-GARRE, D., A. Ortega-Hernández, J. Modrego, R. Gómez-Gordo, L. Espino, N. Martell, and A. Corbatón. "AM3, a natural glycoconjugate, as adjuvant treatment for COVID-19 patients." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.4246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bomfin, Luana Schoenhalz, Dárcio Kitakawa, Marcelo Saito Nogueira, and Luis Felipe das Chagas e. Silva de Carvalho. "Low Level Laser Therapy as adjuvant treatment for lower lip lesion." In Latin America Optics and Photonics Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/laop.2022.m2b.6.

Full text
Abstract:
Low-level laser therapy (LLLT) is a very valid option for treatment of oral lesions. A patient with painful ulcerated lesion in lower lip was treated with 0.05% clobetasol propionate and 7 sessions of LLLT.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Adjuvant treatment"

1

López-Valverde, Nansi, Antonio López-Valverde, and Jose Antonio Blanco-Rueda. Efficacy of metronidazole on peri-implantitis: A systematic review and meta-analysis of randomized studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0015.

Full text
Abstract:
Review question / Objective: In patients with peri-implantitis, is adjuvant local or systemic treatment with metronidazole effective on signs of inflammation and bone destruction? Eligibility criteria: Inclusion criteria: a) RCTs (single or double-blind) performed in patients with peri-implantitis defined as bleeding and/or suppuration on peri-implant probing (≥ 4 mm).b) Studies comparing the efficacy of local/systemic metronidazole adjuvant therapy vs. single surgical or non-surgical treatmentc) Articles published in English.Exclusion criteria: a) Less than five patients per treatment group.b) Lack of clinical data on bone destruction.c) Case series or clinical casesd) Undefined cases and non-relevant studies.
APA, Harvard, Vancouver, ISO, and other styles
2

Garcia, Martin, and Pedro Tinedo. ADJUVANT EFFECT OF PROPOLIS TO PERIODONTAL THERAPY FOR THE TREATMENT OF PERIODONTAL DISEASE: A SYSTEMATIC REVIEW. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0030.

Full text
Abstract:
Review question / Objective: In patients with periodontal disease, what will be the scientific evidence on the adjuvant effect of Propolis to periodontal therapy for the treatment of periodontal disease? Condition being studied: Periodontal Disease or Periodontitis, an inflammatory disease that affects the supporting tissues that surround the tooth, which are currently being studied with natural products that would work as an adjuvant to periodontal therapy and obtain better results. Information sources: Three digital data sources were used, PUBMED, SCOPUS and EMBASE.
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Ying, Yuzhu Wang, Qianzhou Lv, Xiaoyu Li, and Xiaowu Huang. Comparative effectiveness of adjuvant treatment for curative resected hepatocellular carcinoma: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Yilan, and Xiaomin Wang. Yunnan Baiyao Adjuvant Treatment for Patients with Hemoptysis: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2021. http://dx.doi.org/10.37766/inplasy2021.7.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wangi, Yuanyuan, Lin Zhang, Yu Liu, Yu Liu, Hui Yu, Anlin Li, Tingting Liu, et al. The ICI-based therapy landscape in resectable non-small cell lung cancer: a comparative analysis of treatment efficacy and safety between neo-adjuvant, adjuvant and perioperative immunotherapy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2023. http://dx.doi.org/10.37766/inplasy2023.10.0084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wang, Jing, Xiaomin Wang, Xinyi Yang, Yayi Jiang, Wenwen Zhao, and Rensong Yue. Mudan Granules Adjuvant Treatment for Patients with Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhang, Huan, Chao Zhang, Cuicui Sun, and Qiong Zhang. Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2023. http://dx.doi.org/10.37766/inplasy2023.5.0105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Pan-Pan, Yan-Hua Li, and Dong-Qin Xia. Efficacy of Biqi Capsule in the Adjuvant Treatment of Ankylosing Spondylitis : A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Chen qi, kexin Zheng, Lingqi Sun, and Hongbin Sun. Effects of magnesium valproate adjuvant therapy on patients with dementia: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0038.

Full text
Abstract:
Review question / Objective: To evaluate the efficacy of magnesium valproate(VPM) in the adjuvant treatment of patients with dementia(PwD). Participant or population: Adults with dementia (as diagnosed by a clinician, or using any recognized diagnostic criteria) will be included. Information sources: MEDLINE via PubMed, Cochrane Library, EBSCO, Embase, China National Knowledge(CNKI) and Wan fang databases.
APA, Harvard, Vancouver, ISO, and other styles
10

Xing, Lei, Hongmin Guo, and Zhiqian Wang. Efficacy and safety of Suzi Jiangqi Decoction in patients with acute exacerbation of chronic obstructive pulmonary disease A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2021. http://dx.doi.org/10.37766/inplasy2021.8.0035.

Full text
Abstract:
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory symptoms. The respiratory symptoms of patients with acute exacerbation of COPD (AECOPD) worsen rapidly. At present, traditional western medicine treatment can not effectively alleviate the symptoms and attack frequency of patients. Suzi Jiangqi decoction(SZJQ) has a good clinical effect in the treatment of AECOPD. Due to the lack of evidence-based medicine, it can not provide an effective systematic evaluation for the treatment of AECOPD with Suzi Jiangqi decoction. Therefore, it is necessary to provide high-quality evidence evaluation for the clinical efficacy and safety of Suzi Jiangqi Decoction in the treatment of AECOPD. Methods: Two researchers independently retrieved randomized controlled trial (RCT) and quasi-RCTs of SZJQ in the treatment of AECOPD from databases including PubMed, Web of science, the Cochrane Library, CBM, CNKI, Sinomed, VIP and WanFang.The included studies were evaluated for quality according to the RCT quality assessment method provided by Cochrane Reviewer's Handbook 5.3.Review Manager 5.3 software provided by the Cochrane collaboration was used for meta-analysis. Results: This study will provide systematic review on the efficacy and safety of SZJQ as adjuvant therapy in patients with AECOPD by rigorous quality assessment and reasonable data synthesis. Conclusions: This systematic review will provide the good evidence currently on SZJQ as adjuvant therapy in patients with AECOPD.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adjuvant treatment' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography